ReviewMayo Clinic proceedings2018
Management Options for Irritable Bowel Syndrome.
Review in Mayo Clinic proceedings, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06423001 (A Randomized, Cross-over, Placebo-Controlled, Double-Blind Clinical Trial on the Efficacy and Safety of Oral Administration of Postibiotic by FOS Fermentation From Lactobacillus Paracasei in the Treatment of Irritable Bowel Syndrome.), which is not on this map. Cited by 56 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Cross-over, Placebo-Controlled, Double-Blind Clinical Trial on the Efficacy and Safety of Oral Administration of Postibiotic by FOS Fermentation From Lactobacillus Paracasei in the Treatment of Irritable Bowel Syndrome.
Who cites it
56 citing papers in PubMed, 8 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2026Pooled it
- Comparative efficacy and safety of Chinese medicine external therapies for diarrhea-predominant irritable bowel syndrome: a systematic review and network meta-analysis.Frontiers in medicine · 2026Pooled it
- Association between myalgic encephalomyelitis/chronic fatigue syndrome and irritable bowel syndrome: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Pooled it
- A systematic review and meta-analysis of diet and nutrient intake in adults with irritable bowel syndrome.Neurogastroenterology and motility · 2024Pooled it
- The efficacy of vitamin D supplementation for irritable bowel syndrome: a systematic review with meta-analysis.Nutrition journal · 2022Pooled it
- Pooled it
- Acupuncture vs. antispasmodics in the treatment of irritable bowel syndrome: An adjusted indirect treatment comparison meta-analysis.Frontiers in physiology · 2022Pooled it
- Ameliorating effects and mechanisms of transcutaneous auricular vagal nerve stimulation on abdominal pain and constipation.JCI insight · 2021Trial
- Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.United European gastroenterology journal · 2019Trial
- Patients' Knowledge, Attitudes, and Practices Regarding Non-pharmacological Treatments for Irritable Bowel Syndrome.Journal of neurogastroenterology and motility · 2026Article
- Targeting Irritable Bowel Syndrome Through Diet and Mechanism-Based Therapies: A Pathophysiological Approach.Nutrients · 2025Review
- Natural Remedies for Irritable Bowel Syndrome: A Comprehensive Review of Herbal-Based Therapies.International journal of molecular sciences · 2025Review
- Article
- Bacterial Histamine as a Therapeutic Target for Abdominal Pain in Irritable Bowel Syndrome: A Literature Review.Cureus · 2025Review
- Harnessing precision nutrition to individualize weight restoration in anorexia nervosa.Journal of eating disorders · 2025Review
- Article
- Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation onFrontiers in medicine · 2025Article
- Herbal Extracts Mixed with Essential Oils: A Network Approach for Gastric and Intestinal Motility Disorders.Nutrients · 2024Article
- Sinisan Alleviates Stress-Induced Intestinal Dysfunction and Depressive-like Behaviors in Mice with Irritable Bowel Syndrome by Enhancing the Intestinal Barrier and Modulating Central 5-Hydroxytryptamine.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Irritable bowel syndrome (IBS) is associated with diverse pathophysiologic mechanisms. These mechanisms include increased abnormal colonic motility or transit, intestinal or colorectal sensation, increased colonic bile acid concentration, and superficial colonic mucosal inflammation, as well as epithelial barrier dysfunction, neurohormonal up-regulation, and activation of secretory processes in the epithelial layer. Novel approaches to treatment include lifestyle modification, changes in diet, probiotics, and pharmacotherapy directed to the motility, sensation, and intraluminal milieu of patients with IBS. Despite recent advances, there is a need for development of new treatments to relieve pain in IBS without deleterious central or other adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.